Drug Safety

Management of Calcium Channel Antagonist Overdose
pp. 65-79(15)
Authors: Salhanick S.D.; Shannon M.W.

Fenofibrate-Induced Hyperhomocysteinaemia: Clinical Implications and Management
pp. 81-91(11)
Authors: Dierkes J.; Westphal S.; Luley C.

Tolerability of the Triptans: Clinical Implications
pp. 93-107(15)
Authors: Nappi G.; Sandrini G.; Sances G.

Adverse Drug Reactions Related to the Use of Fluoroquinolone Antimicrobials: An Analysis of Spontaneous Reports and Fluoroquinolone Consumption Data from Three Italian Regions
pp. 109-120(12)
Authors: Leone R.; Venegoni M.; Motola D.; Moretti U.; Piazzetta V.; Cocci A.; Resi D.; Mozzo F.; Velo G.; Burzilleri L.; Montanaro N.; Conforti A.

The Pharmacovigilance of Pantoprazole: The Results of Postmarketing Surveillance on 11 541 Patients in England
pp. 121-132(12)
Authors: Wilton L.V.; Key C.; Shakir S.A.W.

Hospital Visits Caused by Adverse Drug Reactions: Incidence and Preventability Assessed in French Primary Care/Emergency Departments
pp. 133-134(2)
Authors: Bannwarth B.; Queneau P.; Carpentier F.; Guliana J-M.; Bouget J.; Trombert B.